Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
| ▸ | PYGL | P06737 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275693 | 1.00 | F10 (0.50) | F10EHMT2SMYD3PYGL | |
| SCHEMBL3340284 | 1.00 | F10 (0.50) | F10EHMT2SMYD3PYGL | |
| SCHEMBL10476622 | 1.00 | F10 (0.50) | F10EHMT2SMYD3PYGL | |
| SCHEMBL4094101 | 1.00 | F10 (0.50) | F10EHMT2SMYD3PYGL | |
| SCHEMBL3342555 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL | |
| SCHEMBL4093951 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL | |
| SCHEMBL4087798 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL | |
| SCHEMBL15016361 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL | |
| SCHEMBL4269437 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL | |
| SCHEMBL3342559 | 0.91 | F10 (0.59) | F10EHMT2SMYD3PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | F10 152/4885EHMT2 4292/4885SMYD3 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.